<DOC>
	<DOCNO>NCT01287247</DOCNO>
	<brief_summary>This prospective , observational trial evaluate `` real world '' use Xeomin® ( incobotulinumtoxinA ) . Physicians may enroll patient eligible treated botulinum toxin cervical dystonia blepharospasm base upon clinical experience . The physician must choose treat patient Xeomin® ( incobotulinumtoxinA ) prior independent enrollment study . Physicians may choose treat subject 2 treatment cycle ( approximately 6 months/subject ) Xeomin® ( incobotulinumtoxinA ) dose determine physician base upon his/her clinical experience botulinum toxin . According dependent clinical practice , investigator expect subject see investigator average 3 visit ( two treatment cycle ) .</brief_summary>
	<brief_title>Trial Evaluating Xeomin® ( incobotulinumtoxinA ) Cervical Dystonia Blepharospasm United States</brief_title>
	<detailed_description>The primary objective trial collect , evaluate , report observational data clinical use Xeomin® `` real world '' set determine muscle inject , dose use , doctor administer injection . The secondary objective trial : To collect evaluate information efficacy Xeomin® . To collect evaluate information effect Xeomin® work productivity quality life . To monitor serious side effect non-serious related side effect Xeomin®</detailed_description>
	<mesh_term>Dystonia</mesh_term>
	<mesh_term>Dystonic Disorders</mesh_term>
	<mesh_term>Torticollis</mesh_term>
	<mesh_term>Blepharospasm</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<criteria>Subjects 18 year age old . The physician must choose treat patient Xeomin® ( incobotulinumtoxinA ) prior independent enrollment study . Subjects eligible treated botulinum toxin cervical dystonia blepharospasm base upon physician ' clinical experience . There restrictive subject entry criterion . Subjects able read , speak understand English . Subjects enrol clinical trial ( currently within past 3 month ) treatment impose protocol eligible trial . Any subject botulinum toxin treatment would contraindicate ; see Xeomin® Prescribing Information detail .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Cervical dystonia</keyword>
	<keyword>Blepharospasm</keyword>
</DOC>